Currently Enrolling Trials
Nasacort AQ Nasal Spray has been approved for the treatment of seasonal and perennial allergic rhinitis symptoms indicated for adults and children over the age of 12.
Contained in an aqueous microcrystalline suspension that does not use chloroflurocarbon (CFC) propellants, Nasacort AQ represents a new formulation of the active ingredient, triamcinolone acetonide. RPR will also continue to market its once-daily aerosol formulation of triamcinolone acetonide.
Each metered pump spray bottle of Nasacort AQ provides at least 120 actuations. It is recommended that once-daily dosing begin at 220 micrograms (two sprays in each nostril) for adults and children 12 years and older.
The safety and efficacy of Nasacort AQ has been demonstrated in ten placebo-controlled, double-blind studies involving more than 1,200 subjects ages 12 years and older with seasonal or perennial allergic rhinitis. These studies showed that compared to placebo, once-daily Nasacort AQ provides statistically significant relief of nasal symptoms including sneezing, stuffiness, discharge, and itching.
Nasacort AQ is generally well tolerated. The most commonly reported side effects observed in clinical trials included sore throat, nosebleed, and cough.
An estimated 40 million Americans suffer from seasonal and perennial allergic rhinitis, which produce symptoms including nasal itch, congestion, runny nose, sneezing, and watery eyes.
Seasonal allergic rhinitis--commonly known as hay fever--is caused by allergens present at specific times of the year, such as tree pollens in the spring. Perennial allergic rhinitis is caused by allergens in the environment all year, such as dust mites, mold, mildew, or pet dander.